Biohaven Pharmaceutical Holding (BHVN) PT Raised to $70 at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Alan Carr raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $70.00 (from $56.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
